| Company Name: | Alexion Pharmaceuticals, Inc. | | Ticker Symbol: | ALXN | | | WWW Address: | www.alexionpharm.com |
| CEO: | Dr. Leonard Bell,M.D. | | No. of Employees: | 1,373 |
| Common Issue Type: | CS | | Business Description: | Alexion Pharmaceuticals, Inc. is a biopharmaceutical company engaged in serving patients with severe and ultra-rare disorders through the development and commercialization of life-transforming therapeutic products.
|
| | | Industry Information: | DRUGS - Biotechnology [more like this] |
| | Price | Day Change | Bid | Ask | Open | High | Low | Volume | | 102.91 |  1.09 | 98.19 | 104.99 | 102.57 | 104.29 | 101.77 | 977654 |
| Market Cap (mil) | Shares Outstanding (mil) | Beta | EPS | DPS | P/E | Yield | 52-Wks-Range |
| 20,082.5 | 195.1 | 0.47 | 1.28 | 0.00 | 71.0 | 0.0 | 119.54 - 81.82 |
| | KEY FIGURES (Latest Twelve Months - LTM) | | Yesterday's Close | 102.90 | $ | | PE Ratio - LTM | 71.0 | |
| Market Capitalisation | 20,082.5 | mil |
| Latest Shares Outstanding | 195.1 | mil |
| Earnings pS (EPS) | 1.28 | $ |
| Dividend pS (DPS) | 0.00 | ¢ |
| Dividend Yield | 0.0 | % |
| Dividend Payout Ratio | | % |
| Revenue per Employee | 826,012 | $ |
| Effective Tax Rate | 35.9 | % |
| Float | 171.5 | mil |
| Float as % of Shares Outstanding | 88.0 | % |
| Foreign Sales | 734 | mil |
| Domestic Sales | 400 | mil |
| Selling, General & Adm/tive (SG&A) as % of Revenue | 33.10 | % |
| Research & Devlopment (R&D) as % of Revenue | 20.50 | % |
| Gross Profit Margin | 91.1 | % |
| EBITDA Margin | 37.5 | % |
| Pre-Tax Profit Margin | 36.4 | % |
| Assets Turnover | 0.5 | % |
| Return on Assets (ROA) | 9.5 | % |
| Return on Equity (ROE) | 12.2 | % |
| Return on Capital Invested (ROCI) | 11.7 | % |
| Current Ratio | 5.2 | |
| Leverage Ratio (Assets/Equity) | 1.3 | |
| Interest Cover | 66.3 | |
| Total Debt/Equity (Gearing Ratio) | 0.07 | |
| LT Debt/Total Capital | 5.0 | % |
| Working Capital pS | 6.43 | $ |
| Cash pS | 5.24 | $ |
| Book-Value pS | 10.71 | $ |
| Tangible Book-Value pS | 6.10 | $ |
| Cash Flow pS | 1.43 | $ |
| Free Cash Flow pS | 1.90 | $ |
 |
| KEY FIGURES (LTM): Price info |
| Price/Book Ratio | 9.61 | |
| Price/Tangible Book Ratio | 16.86 | |
| Price/Cash Flow | 71.8 | |
| Price/Free Cash Flow | 54.2 | |
| P/E as % of Industry Group | 269.0 | % |
| P/E as % of Sector Segment | 57.0 | % |
| | | Balance Sheet (at a glance) in Millions |
| | | | | | DIVIDEND INFO | | Type of Payment | - |
| Dividend Rate | 0.00 |
| Current Dividend Yield | 0.0 |
| 5-Y Average Dividend Yield | 0.0 |
| Payout Ratio | 0.0 |
| 5-Y Average Payout Ratio | 0.0 |
| |
| |
| |
| |
| |
|  | | Share price performance previous 3 years |
|
 | | | Share price performance intraday |
|
 | | | | | PRICE/VOLUME | High | Low | Close | % Price Chg | % Price Chg vs. Mkt. | Avg. Daily Vol | Total Vol |
| 1 Week | - | - | - | -1.2 | 97 | 13,749 | 70,170 |
| 4 Weeks | 108.13 | 88.86 | 92.60 | 11.1 | 104 | 16,175 | 323,508 |
| 13 Weeks | 108.13 | 81.82 | 86.01 | 19.6 | 109 | 17,654 | 1,112,197 |
| 26 Weeks | 108.13 | 81.82 | 90.91 | 13.2 | 92 | 16,298 | 2,020,988 |
| 52 Weeks | 119.54 | 81.82 | 84.26 | 22.1 | 95 | 16,596 | 4,132,359 |
| YTD | 108.13 | 81.82 | - | 9.8 | 94 | 17,930 | 1,703,384 |
| Moving Average | 5-Days | 10-Days | 10-Weeks | 30-Weeks | 200-Days | Beta (60-Mnth) | Beta (36-Mnth) |
| 104.53 | 101.50 | 96.48 | 94.49 | 98.76 | 0.47 | 0.54 |
| | | | GROWTH RATES | 5-Year
Growh | R² of 5-Year Growth | 3-Year
Growth |
| Revenue | 50.34 | 95.8 | 36.80 |
| Income | 0.00 | 0.0 | 5.71 |
| Dividend | 0.00 | 0.0 | 0.00 |
| Capital Spending | 42.43 | NA | 150.77 |
| R&D | 28.58 | NA | 38.53 |
| Normalized Inc. | 0.00 | NA | 0.00 |
| | | CHANGES | YTD vs.
Last YTD | Curr Qtr vs.
Qtr 1-Yr ago | Annual vs.
Last Annual |
| Revenue % | 38.5 | 38.5 | 44.8 |
| Earnings % | 0.0 | 0.0 | 0.0 |
| EPS % | 78.3 | 78.3 | 40.7 |
| EPS $ | 0.18 | 0.18 | 0.37 |
| | | | SOLVENCY RATIOS | | SHORT-TERM SOLVENCY RATIOS (LIQUIDITY) |
| Net Working Capital Ratio | 43.45 |
| Current Ratio | 4.2 |
| Quick Ratio (Acid Test) | 3.6 |
| Liquidity Ratio (Cash) | 2.75 |
| Receivables Turnover | 4.2 |
| Average Collection Period | 86 |
| Working Capital/Equity | 57.6 |
| Working Capital pS | 5.83 |
| Cash-Flow pS | 1.43 |
| Free Cash-Flow pS | -1.11 |
| FINANCIAL STRUCTURE RATIOS |
| Altman's Z-Score Ratio | 20.32 |
| Financial Leverage Ratio (Assets/Equity) | 1.3 |
| Debt Ratio | 24.6 |
| Total Debt/Equity (Gearing Ratio) | 0.08 |
| LT Debt/Equity | 0.05 |
| LT Debt/Capital Invested | 13.6 |
| LT Debt/Total Liabilities | 15.7 |
| Interest Cover | 54.7 |
| Interest/Capital Invested | 0.33 |
| | | | VALUATION RATIOS | | MULTIPLES |
| PQ Ratio | 11.44 |
| Tobin's Q Ratio | 7.68 |
| Current P/E Ratio - LTM | 71.00 |
| Enterprise Value (EV)/EBITDA | 46.55 |
| Enterprise Value (EV)/Free Cash Flow | -93.22 |
| Dividend Yield | 0.0 |
| Price/Tangible Book Ratio - LTM | 16.86 |
| Price/Book Ratio - LTM | 9.61 |
| Price/Cash Flow Ratio | 71.8 |
| Price/Free Cash Flow Ratio - LTM | 54.2 |
| Price/Sales Ratio | 16.35 |
| P/E Ratio (1 month ago) - LTM | 65.3 |
| P/E Ratio (26 weeks ago) - LTM | 81.2 |
| P/E Ratio (52 weeks ago) - LTM | 84.3 |
| 5-Y High P/E Ratio | 119.9 |
| 5-Y Low P/E Ratio | 9.4 |
| 5-Y Average P/E Ratio | 66.9 |
| Current P/E Ratio as % of 5-Y Average P/E | 106 |
| P/E as % of Industry Group | 269.0 |
| P/E as % of Sector Segment | 57.0 |
| Current 12 Month Normalized P/E Ratio - LTM | 58.6 |
| PER SHARE FIGURES |
| LT Debt pS | 0.52 |
| Current Liabilities pS | 1.85 |
| Tangible Book Value pS - LTM | 6.10 |
| Book Value pS - LTM | 10.71 |
| Capital Invested pS | 10.62 |
| Cash pS - LTM | 5.24 |
| Cash Flow pS - LTM | 1.43 |
| Free Cash Flow pS - LTM | 1.90 |
| Earnings pS (EPS) | 1.28 |
| | | | OPERATING RATIOS | | PROFITABILITY RATIOS |
| Free Cash Flow Margin | -19.13 |
| Free Cash Flow Margin 5YEAR AVG | 8.28 |
| Net Profit Margin | 22.5 |
| Net Profit Margin - 5YEAR AVRG. | 9.3 |
| Equity Productivity | 0.58 |
| Return on Equity (ROE) | 12.9 |
| Return on Equity (ROE) - 5YEAR AVRG. | 5.9 |
| Capital Invested Productivity | 0.55 |
| Return on Capital Invested (ROCI) | 12.3 |
| Return on Capital Invested (ROCI) - 5YEAR AVRG. | 5.6 |
| Assets Productivity | 0.60 |
| Return on Assets (ROA) | 9.8 |
| Return on Assets (ROA) - 5YEAR AVRG. | 4.6 |
| Gross Profit Margin | 91.1 |
| Gross Profit Margin - 5YEAR AVRG. | 91.0 |
| EBITDA Margin - LTM | 37.5 |
| EBIT Margin - LTM | 36.9 |
| Pre-Tax Profit Margin | 35.1 |
| Pre-Tax Profit Margin - 5YEAR AVRG. | 28.8 |
| Effective Tax Rate | 35.9 |
| Effective Tax Rate - 5YEAR AVRG. | -31.1 |
| EFFICIENCY RATIOS |
| Cash Conversion Cycle | 402 |
| Revenue per Employee | 826,012 |
| Net Income per Employee | 185,595 |
| Average Collection Period | 94 |
| Receivables Turnover | 4.2 |
| Day's Inventory Turnover Ratio | 308 |
| Inventory Turnover | 1.2 |
| Inventory/Sales | 8.3 |
| Accounts Payble/Sales | 9.64 |
| Assets/Revenue | 1.67 |
| Net Working Capital Turnover | 1.00 |
| Fixed Assets Turnover | 1.01 |
| Total Assets Turnover | 0.6 |
| Revenue per $ Cash | 1.15 |
| Revenue per $ Plant | 6.85 |
| Revenue per $ Common Equity | 0.58 |
| Revenue per $ Capital Invested | 0.55 |
| Selling, General & Adm/tive (SG&A) as % of Revenue | 33.9 |
| SG&A Expense as % of Revenue - 5YEAR AVRG. | 39.5 |
| Research & Devlopment (R&D) as % of Revenue | 19.6 |
| R&D Expense as % of Revenue - 5YEAR AVRG. | 19.6 |
|
|  
| | |  |  | |
| |
